A Study of Controlled Lactulose Withdrawal
NCT00914056 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 7
Last updated 2013-03-20
Summary
After resolution of the initial episode of hepatic encephalopathy (HE), lactulose is routinely continued indefinitely as maintenance therapy. Although widely used for this indication, lactulose has never been shown in randomized, controlled trials to be effective for preventing exacerbations of HE. Indeed, lactulose was found to be ineffective at preventing HE when administered prophylactically to patients undergoing portosystemic shunt insertion. While some patients may be lactulose dependent following an initial episode of HE, it is likely that most could have their lactulose discontinued with no adverse consequences.
This goal is worth pursuing because lactulose is not innocuous. It has an unpleasant taste, and it routinely produces gastrointestinal symptoms, including bloating, gas and diarrhea. In high doses it can cause incontinence, dehydration and electrolyte derangements. Patients universally dislike taking lactulose and often are noncompliant with treatment. A recent trial showed that patients on lactulose had a substantial risk of hospital admissions due to lactulose-related complications and treatment non-compliance.
Conditions
- Hepatic Encephalopathy
Interventions
- DRUG
-
lactulose
withdrawal of lactulose
Sponsors & Collaborators
-
Hunter Holmes Mcguire Veteran Affairs Medical Center
lead FED
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-09-30
- Primary Completion
- 2009-05-31
- Completion
- 2012-05-31
Countries
- United States
Study Locations
More Related Trials
-
Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhotic Patients
NCT05279586 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Efficacy Study of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) Versus Lactulose in Patients With Hepatic Encephalopathy.
NCT01283152 ·Status: COMPLETED ·Phase: NA
-
Antioxidants and Zinc Improving Minimal Hepatic Encephalopathy In Truck Drivers; a Pilot Study
NCT02520817 ·Status: COMPLETED
-
Fecal Microbiota Transplantation (FMT) in the Management of Hepatic Encephalopathy (HE): a Pilot Study
NCT02255617 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Quality of Life and Nutritional Improvements in Cirrhotic Patients
NCT01842113 ·Status: TERMINATED ·Phase: PHASE4
-
Effect of Lactulose on Minimal Hepatic Encephalopathy and Health-Related Quality of Life
NCT00375375 ·Status: COMPLETED ·Phase: PHASE4
-
S. Endotoxin, Inflammatory Mediators and MRS Before and After Treatment in MHE
NCT01446523 ·Status: COMPLETED ·Phase: NA
-
To Assess Efficacy of Nutritional Therapy in Secondary Prophylaxis of Hepatic Encephalopathy Versus Lactulose in Patients With Liver Cirrhosis.
NCT03161106 ·Status: WITHDRAWN ·Phase: NA
-
Effect of Lactose in Patients With Chronic Liver Disease and Minimal Hepatic Encephalopathy
NCT01113567 ·Status: TERMINATED ·Phase: NA
-
Efficacy of Lactoferrin as an Adjunct Therapy in Patients With Hepatic Encephalopathy
NCT06072521 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRS
NCT02048969 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy
NCT00281502 ·Status: UNKNOWN ·Phase: PHASE2
-
Synbiotics Interventions for Managing Cirrhosis and Its Complications
NCT05687409 ·Status: COMPLETED ·Phase: PHASE4
-
Fecal Microbiota Transplant as Treatment of Hepatic Encephalopathy
NCT03420482 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy.
NCT01846806 ·Status: TERMINATED ·Phase: NA
-
Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life
NCT01008293 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Fructans, Lactitol and Lactose in Minimal Hepatic Encephalopathy
NCT02022137 ·Status: COMPLETED ·Phase: NA
-
N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure
NCT00248625 ·Status: COMPLETED ·Phase: PHASE3
-
BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HE
NCT06538077 ·Status: RECRUITING ·Phase: PHASE4
-
Lipid Emulsions and Liver Function - Results After 5 Years.
NCT04347902 ·Status: COMPLETED ·Phase: PHASE4
-
Use of Omega-3 Fat Emulsion (Omegaven) in Infants With Parenteral Nutrition Associated Liver Disease
NCT00862446 ·Status: COMPLETED ·Phase: PHASE4
-
RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial
NCT00364689 ·Status: TERMINATED ·Phase: PHASE3
-
Hepatic Metabolism of Galactose and the Galactose Analog FDGal in Patients With Liver Disease and Healthy Subjects
NCT01002261 ·Status: COMPLETED
-
Glycosade v UCCS in the Dietary Management of Hepatic GSD
NCT02318966 ·Status: COMPLETED ·Phase: NA
-
Compassionate Use of Omegaven® for the Treatment of Intestinal Failure Associated Liver Disease in Children
NCT02328768 ·Status: APPROVED_FOR_MARKETING